Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Bioepis Co., Ltd.

Latest From Samsung Bioepis Co., Ltd.

ICER Suggests Big Price Cut For Novartis’s New PNH Drug

The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”

Pricing Debate Blood & Coagulation Disorders

Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

Biosimilars Reimbursement

Byooviz Or Beovu? Canadian Court Halts Samsung, Biogen Biosimilar Trademark

In a rather novel case in Canada, Novartis has established before a Federal district court that there is a likelihood that the trademark rights for its Beovu brand will be confused with Samsung Bioepis and Biogen’s Byooviz biosimilar.

Legal Issues Biosimilars

Samsung Bioepis Biosimilars Report Slams ‘Stagnant’ US Adalimumab Uptake

In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.

Biosimilars Market Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Samsung Biologics
    • Samsung Bioepis JV
    • Samsung Bioepis BR Pharmaceutical LTDA